ReviewBioMed research international2018
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma.
Review in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- Structure and function of therapeutic antibodies approved by the US FDA in 2025.Antibody therapeutics · 2026Review
- Proteomics Reveals Age as Major Modifier of Inflammatory CSF Signatures in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- In mouse model of mixed granulocytic asthma with corticosteroid refractoriness, Bronchom mitigates airway hyperresponsiveness, inflammation and airway remodeling.Molecular medicine (Cambridge, Mass.) · 2024Article
- Is Omalizumab Related to Ear and Labyrinth Disorders? A Disproportionality Analysis Based on a Global Pharmacovigilance Database.Diagnostics (Basel, Switzerland) · 2022Article
- Eosinophilic esophagitis: Immune mechanisms and therapeutic targets.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022Review
- Taking a Breather: Advances in Interleukin 5 Inhibition for Asthma Relief.International journal of molecular sciences · 2022Review
- Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells.Cell discovery · 2022Article
- Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study.Allergy · 2022Article
- Biologics in severe asthma: the role of real-world evidence from registries.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- To the Editor: "Complete Resolution of Multiple Warts after a First Dose of the Receptor Interleukin-5 Inhibitor".Journal of clinical immunology · 2022Article
- Holy Grail: the journey towards disease modification in asthma.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life.The World Allergy Organization journal · 2021Article
- Biological Therapies in Children and Adolescents with Severe Uncontrolled Asthma: A Practical Review.Biologics : targets & therapy · 2021Review
- The Herbal Cocktail GSYJ Attenuated Airway Inflammatory Cell Infiltration in a Chronic Asthmatic Mouse Model.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Regulatory T cells mediated immunomodulation during asthma: a therapeutic standpoint.Journal of translational medicine · 2020Review
- Biologics to Treat Severe Asthma in Children and Adolescents: A Practical Update.Pediatric allergy, immunology, and pulmonology · 2020Review
- Group 2 Innate Lymphoid Cells Must Partner with the Myeloid-Macrophage Lineage for Long-Term Postviral Lung Disease.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.Frontiers in immunology · 2020Article
- Addition of a Viral Immunomodulatory Domain to Etanercept Generates a Bifunctional Chemokine and TNF Inhibitor.Journal of clinical medicine · 2019Article
- Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives.Paediatric drugs · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current developments of the new biological drugs targeting interleukin 5 (IL-5) and IL-5 receptor allowed to expand the treatment options for severe hypereosinophilic asthma. Clinicians will then be able to choose between antibodies targeting either circulating IL-5 or its receptor expressed on eosinophils and basophils. The available clinical trials consistently reported favorable results about the reduction of exacerbations rate, improvement in quality of life, and sparing of the systemic steroid use, with a favorable safety profile. Two of these new drugs are administered subcutaneously, mepolizumab every 4 weeks and benralizumab every 8 weeks, whereas reslizumab is given intravenously monthly on a weigh-based dose. In the future, the research actions will be involved in the identification of a single biomarker or multiple biomarkers for the optimal choice of biological agents to be properly prescribed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.